Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I’ll send my congratulations card to the investor on the 14th for getting in at the same price as me with zero risk...
However, yes it sounds like a great opportunity I agree
I have a good feeling about our new company. I think they are ready to go. Few grounds ready for an admission day to average down :-) I know few will do the same. Next week 14th May will be crazy day!! Can't wait to see their presentation this week. In it to win it!
GL all
6pm is an odd time, and totally impossible for me to attend due to other commitments (which can't be re-arranged). Hopefully we'll get a summary or key points on here at some point from those who can!
A reminder:
Investor Webinar
Representatives from Bould’s management and Cizzle Biotechnology will be hosting an online presentation and Q&A session at 6.00 p.m. BST on Thursday 6 May 2021. This session is open to all shareholders and other interested parties.
Those who wish to attend should register via the link below and they will be provided with access details.
https://us02web.zoom.us/webinar/register/WN_J4CZWpskQFqW4IbinMSAow
Antos would not accept a big dilution of his holding for nothing, I am beginning to sence there has been far more progress accomplished than we know. Let us hope the Q & A webinar will be very informative.
Aspen
"Shortly after the Acquisition, it is proposed that the group, as enlarged by the Acquisition (the “Enlarged Group”) will enter into agreements with selected manufacturers and contract research organisations to conduct the reagent generation, test manufacture and the clinical validation required to achieve CE marking and/or FDA510(K) clearance"
Sounds to me like they are pretty well advanced if they are looking at that.
Been reading up on some of the medical journals ( i really should get out more!) and it looks to me that this is bigger than first seems. We appear to be focusing on lung cancer, but as i said earlier, it also acts as a detector for breast, colon, prostate, gall cancers etc. reading some of the papers submitted, it appears that the CIZ1 protein has 22 variants (that is known at present) and has also been associated with gastric cancers, Alzheimers, rheumatoid athritis, and Ewings tumour.
One that stood out was the incidence of brain tumours. Apparently these are only detectable when they have become solid tumour, and there is no cure, with a very poor prognosis. They can't be detected earlier due to "blood brain barrier" If our test can overcome this barrier, and detect the protein before it becomes tumour, just imagine the medical need. The more i read into this research, the better this looks.
Neil
Yes mate,
I've been mulling over a few things people have gleaned from that prospectus and what you've just posted adds more weight to the thought.
At which stage is this product. And why 20 days a year?
1. "Previous commercial engagement":
https://www.finance-yorkshire.com/news/news139.asp
2. "Subsequent technological improvement":
The fact that what we have can identify 95% of the patients who actually have the disease shows how useful this is. There may better, but atleast we are not looking at 60%, 70% or 80% sensitivity.
Here's hoping with what more we find out, that the market believes CIZ is heavily undervalued at 10p.
Time will tell, I believe this might have some serious potential.
Gla
Hopefully after the Q & A session, we should be better informed.
Aspen
taken from the last update= ”..... it allows it to acquire technology which has benefitted from a previous commercial engagement and subsequently technological improvement, but before final commercial terms have been reached with a licencing partner......”
reading this paragraph, i am assuming they are already in discussion with a partner? but happy to be corrected.
It is the final chapter for BOU, but definitely the first chapter for CIZZ, let us hope this will be a rollicking good read.
Aspen
Since Cizzle started in 2006 they will have progressed the research many fold, and will probably been known within the medical world beyond just Fujibio. With this greater exposure to the financial markets will probably also help.
Anything that quickens diagnostics and also reduces the need for invasive diagnostics must be good and welcomed, anyone who has been through invasive diagnostics will probably agree? GLA, the story continues, but might now be on the final chapter within this book?
yes, a few twitt. threads with the new ticker, spread the word..
with our tiny market cap. compared to the likes of #ONC (earlyCDT), I think it will be a matter of prove it and sell it or JV with a big pharma. in fast order. AG definitely wants a fast pace unlock the value here and I am sure this has been discussed with the BODs and Prof Coverley before listing. I submitted couple of Qs for the Webinar including the commerce partner and hopefully will get more clarification
I don't like ramping but if there is something here to get excited about, it doesn't hurt to have this around the top of the top chat boards list when we come back!!
A great way to attract some new interest in a sector that is hot at the moment and will be for a while.
Regardless of what happens in 2 weeks time, the chat board is more upbeat and positive, which is a good thing in it's self.
Aspen
As i understand it, Fujibio were working with a different set of antibodies to Cizzle, which were not compatible with the company's requirements at that time.
Neil
Yes, 2013. My error
I saw an article from 2013 about Fujibio and Cizzle partnership to co develop and licence the product no idea whether it is still in place but if so and with Fujibio's worldwide reach being part of the HU Group then who knows what could happen over the next few years after listing it could be a great investment for us all.....or a damp squib but I shall keep my fingers crossd for the former
Didn’t Cizzle enter into a licensing agreement with Japanese investor Fujirebio in 2003? Is that still in place? Or am I having a senior moment?
the only issue with the OO, that there will be more shares in circulation, possibly double, meaning the sp is slower to move, (atm 49% of shares are in PIs hands i was told), and also not everyone has spare cash to contribute as someone mentioned earlier.
Wideglide, reading the prospectus, there is still some good news here.
There are other companies looking at liquid biopsy diagnostics, but current prototype tests have relied on Western Blot technique.
This technique is expensive, only demonstrates that the test is able to indicate positive result, gives a high percentage of false positive results, and is less reliable when a hospital setting requiring high throughput is required.
The work Cizzle is developing, refines this technique to the stage where it becomes suitable for scaling up to commercial and manufacture. By the sound of things we are ahead of the competition here.
Something to note is the potential for revenue. There are a number of avenues the BOD are exploring. From global licensing of our technology, direct sales, joint ventures, further product line etc.
One thing of note is China. They have the largest increase in lung cancer cases due to the increased level of people taking up smoking (which goes against the rest of the world where most countries are seeing gradual declines) It seems that the BOD are already actively looking at China, and to engage with a Chinese CRO and marketing partner to enter the lung cancer detection market. It just so happens that our Executive Chairman and cancer specialist (Allan Syms) has connections with China having previously held the position of specialist adviser on China to the Department of International Trade.
I am seeing plenty of positives here. Time is the issue.
PS you queried earlier my stage of entry into Bould. Well i was here in the days of Photonstar, and have a fairly significant amount of shares (well into the 10's of millions) so i will be very heavily down at 10p.
Neil
Neil
Wideglide
You never seem to miss an opportunity to have a dig, perhaps you should relax and accept where we are, we are all in the same boat.
Aspen
He hasn't lost penny as far as i can work out.
I said last year that there were reasons he bought photonstar for £1
One being the tax loss that he can use against future profits of his new company. I believe this to be worth over £1million. Also the availability to him of the tax relief in respect of R&D expenditure. I did say that because of a clause in the sale, we were due to a 50% payment from him should he realise that relief. Well he has. To the tune of £107,000.00 to date. So we are due approx £53,500.00 (incidentally this should have been paid to us by April 2020, and which i believe, still has not been paid)
Add to that the fact that he has the option on admission to exercise 7,603,432 shares as the warrants from Peterhouse. At what exercise price? He didn't purchase those at 10p did he? And that is on top of his initial holding.
So you see, as i said back in November i think it was, he couldn't lose.
Neil